title: [Management of prolactinoma].
abstract: The prevalence of pituitary adenoma is of 1/1000 and has been fora long time underestimated. Prolactinomas represent the most frequent subtype (60%). From the mid eighties, their treatment is usually simple and efficient, allowing clinical, biological and tumoral control in most cases. However, management of carcinoma or resistant prolactinoma can be challenging. In these particular cases, a multimodal therapy approach is needed. Recently, progress in genetics of pituitary adenoma has allowed a better understanding and management of these particular cases. In consequence, genetic evaluation is recommended in FIPA (Familial Isolated Pituitary Adenoma) cases and in young patients with macroprolactinomas.
authors.affiliation: Département d'endocrinologie, CHU Liège, Avenue de l'Hôpital I, 4020 Liège, Belgique. Ivroonen@chu.ulg.ac.be
authors.forename: L
authors.initials: L
authors.lastname: Vroonen
authors.forename: A
authors.initials: A
authors.lastname: Daly
authors.forename: A
authors.initials: A
authors.lastname: Beckers
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000077465:Cabergoline; D003937:Diagnosis, Differential; D004873:Ergolines / Q000627:therapeutic use; D006801:Humans; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000628:therapy*; D015175:Prolactinoma / Q000175:diagnosis / Q000628:therapy*; D018714:Radiotherapy, Adjuvant
chemical_list: D000970:Antineoplastic Agents; D004873:Ergolines; D000077465:Cabergoline